Actinium Pharmaceuticals reports results from Phase 3 SIERRA trial of Iomab-B

Actinium Pharmaceuticals highlighted results from three poster presentations at the 2024 Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT being held in San Antonio, Texas. The posters detailed results and findings from the Phase 3 SIERRA trial of Iomab-B including; improved rates of Complete Remission, durable Complete Remission and survival in patients with a TP53 mutation, key aspects of radiopharmaceutical dosimetry as related to Iomab-B, and early results from a Phase 1 study demonstrating safety and lymphodepletion from Iomab-ACT conditioning with CD19 CAR-T therapy. Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B in the Phase 3 SIERRA Trial. The results demonstrate Iomab-B’s ability to overcome the negative impact of a TP53 mutation in these patients who otherwise would have limited treatment options and dismal prognosis. Five presentations include two upcoming oral presentations detailing improved outcomes in SIERRA trial patients ages 65+ and demonstration of robust engraftment with Iomab-B.